Provista Diagnostics to Present Data from a Prospective Clinical Trial at the 2014 San Antonio Breast Cancer Symposium. 

Data Highlights the Role of Serum Protein Biomarkers in Conjunction with Tumor Associated Autoantibodies to Distinguish Benign from Invasive Breast Lesions

New York, NY – December 10, 2014 – Provista Diagnostics, Inc., a privately-held molecular diagnostics company focused on

developing and commercializing a new generation of proprietary blood-based diagnostic, prognostic and monitoring tests designed to address the unmet needs in women’s cancer, such as breast and gynecologic cancers, today announced that its President and CEO, David Reese, PhD, will present data from a prospective, randomized, multi-center clinical trial at the 37th Annual San Antonio Breast Cancer Symposium (SABCS) taking place December 9-13, 2014, at the Henry B. Gonzalez Convention Center in San Antonio, Texas.

The details for the poster session for Provista Diagnostics are as follows:

Session:                                    Detection/Diagnosis - Other

Poster Title:                          Provista-001: a multi-center prospective study of protein signature used in the differentiation of benign breast lesions from invasive breast cancer in women under the age of 50 with a BI-RADS® 3 or 4.

Poster Number:                  P5 03 05

Presenter:                              David E. Reese, PhD

Date & Time:                        Friday, December 12, 2014 from 5:00-7:00 p.m. CT

Location:                                 Halls A-B

Commenting on the upcoming presentation, Dr. Reese stated, “It is increasingly appreciated that over-diagnosis of breast lesions represents a significant problem in detection and screening of breast cancer especially in women under the age of 50 years.  Despite this issue, few new technologies have been developed to augment standard of care in the more precise detection of breast cancer. At SABCS, we present data from a prospective, randomized multi-center study of 351 patients identifying a protein signature composed of Serum Protein Biomarkers (SPB) and tumor derived autoantibodies (TAAbs) that can greatly increase the precision of the diagnosis of breast cancer in women under the age of 50.”

Provista Diagnostics management will be available to discuss its new generation of proprietary blood-based diagnostic, prognostic and monitoring tests at Exhibit Booth T19 from Wednesday, December 10 through Friday, December 12, 2014, during the exhibit hours of 11:00 a.m.-5:00 p.m. CT.

About Provista

Provista Diagnostics is a privately held molecular diagnostics company focused on developing and commercializing a new generation of proprietary blood-based proteomic diagnostic, prognostic and monitoring tests designed to address the unmet needs in women’s cancer, such as breast and gynecologic cancers. Provista Diagnostics’ state-of-the-art, high-complexity clinical laboratory is accredited by the College of American Pathologists (CAP) and with the Clinical Laboratory Improvement Amendments (CLIA).

Additional information about Provista Diagnostics is available at ProvistaDx.com

Information about Provista Diagnostics’ clinical trials is available at ClinicalTrials.gov

Safe Harbor Statement

Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Provista’s actual results may differ materially due to a number of factors, many of which are beyond Provista’s ability to predict or control, including among others, viability and effectiveness of our sales approach and overall marketing strategies, the outcome of development or regulatory review of our products, commercial success or acceptance by the medical community, competitive responses, our ability to raise additional capital, and the ability to successfully file a registration statement with the SEC. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. Provista operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Provista undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

###